Nozocalcin 2200 IU/ml
Salmon Calcitonin
Category: Nasal Spray
Manufacturer: Beximco Pharmaceuticals Ltd.
Allopathic
MFG. Licence No. Biological
119
MFG. Licence No. Non-Biological
379
Address
Tongi I/A, Gazipur
Medicine Selling service is not available yet.
Uses of Nozocalcin:
- Post menopausal osteoporosis
- Paget's disease
- Hypercalcemia
Hypercalcaemia, Paget's disease of bone, Postmenopausal osteoporosis.
Hypersensitivity.
Hormone in bone formation by Inhibiting bone resorption
Calcitonin is a polypeptide hormone produced by the ultimobranchial gland in non-mammalian vertebrates or by the mammalian thyroid parafollicular cells. It inhibits osteoclastic bone resorption and reduces bone turnover. It decreases tubular reabsorption and promotes renal excretion of Ca, Cl, Na, Mg, K and phosphate.
How to use
Salmon Calcitonin:
Use this medicine in the dose and duration as advised by your doctor. Check the label for directions before use. Insert the bottle tip into one nostril and close the other nostril. Direct the spray towards the sides of your nostril, away from the cartilage dividing the two sides of your nose. As you spray, breath gently and keep the head upright. Repeat the same process for the other nostrils.
Adult Dose:
Parenteral
Hypercalcemia
Initial dose: 4 IU/kg SC/IM q12hr May increase to 8 IU/kg SC/IM q12hr; may increase up to a maximum 8 IU/kg q6hr if unresponsive
Paget Disease
Initial dose: 100 IU SC/IM qDay
Maintenance: 50 IU/day or 50-100 IU every 1-3 days
Osteoporosis, Postmenopausal
Indicated for the treatment of postmenopausal osteoporosis in women greater than 5 yr postmenopause
100 IU SC/IM every other day with calcium and vitamin D
Nasal Spray:
1 spray (200 IU) qDay, alternate nostrils daily
Child Dose:
Safety and efficacy not established
Concurrent use w/ cardiac glycosides (e.g. digitalis) or Ca-channel blockers requires dosage adjustments of these drugs. May decrease serum concentration of lithium.
Hypersensitivity.
Common
- Runny nose
- Nasal irritation
>10%
Rhinitis (12%)
1-10%
Arthralgia (4%),Back pain (5%),Expistaxis (4%),Injection site reactions (10%),Nausea (10%),Headache (3%),Flushing of face or hands (2-5%)
<1%
Abdominal pain,Possible allergic reactions,Appetite decreased,Edema of feet,Eye pain,Feverish sensation,Nausea,Nocturia,Possible local irritative effects in the respiratory tract,Salty taste
Frequency Not Defined
Tremors
Potentially Fatal: Anaphylactic shock.
Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Precaution:
Children <18 yr, renal impairment. Pregnancy, lactation. Serious hypersensitivity reactions, including fatal anaphylaxis, reported; consider skin testing prior to treatment. Hypocalcemia associated with tetany has been reported; ensure adequate intake of calcium and vitamin D
Lactation: excretion in milk unknown/not recommended
Symptoms: Flushing, nausea, vomiting and dizziness. Management: Symptomatic and supportive treatment.
Store between 2-8° C.
Hormone in bone formation by Inhibiting bone resorption
It inhibits osteoclastic bone resorption and reduces bone turnover. It decreases tubular reabsorption and promotes renal excretion of Ca, Cl, Na, Mg, K and phosphate.
Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Samm Care